Xencor Inc. Stock
Xencor Inc. Stock
There is an upward development for Xencor Inc. compared to yesterday, with an increase of €0.40 (2.230%).
With 9 Buy predictions and only 1 Sell predictions the community sentiment for the stock is positive.
With a target price of 31 € there is a hugely positive potential of 65.78% for Xencor Inc. compared to the current price of 18.7 €.
Pros and Cons of Xencor Inc. in the next few years
Pros
?
M***** P*******
?
G***** c******* t* c**********
?
C******** o* t** e**********
Cons
?
B****
?
W********* I********* f** t** n*** y****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Xencor Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Xencor Inc. | 2.230% | -5.556% | -9.223% | -22.083% | -9.223% | -46.418% | - |
| Novocure Ltd | 3.070% | 4.053% | -2.114% | -79.652% | -17.268% | -93.443% | - |
| Sage Therapeutics Inc. | -0.350% | 2.037% | -26.156% | -70.428% | -36.125% | -80.292% | - |
| Iovance Biotherapeutics Inc. | -1.440% | 2.211% | -16.359% | 119.362% | 39.152% | -60.289% | - |
Comments
Xencor, Inc. (NASDAQ: XNCR) had its price target lowered by analysts at BTIG Research from $56.00 to $38.00. They now have a "buy" rating on the stock.
Show more
Ratings data for XNCR provided by MarketBeat
Xencor, Inc. (NASDAQ: XNCR) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $32.00 price target on the stock.
Show more
Ratings data for XNCR provided by MarketBeat
Xencor, Inc. (NASDAQ: XNCR) had its price target lowered by analysts at BMO Capital Markets from $38.00 to $34.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for XNCR provided by MarketBeat
News
Xencor Appoints Bart Cornelissen as Chief Financial Officer
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced the appointment of
Xencor to Present at Upcoming Investor Conferences
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company
Xencor Reports Fourth Quarter and Full Year 2023 Financial Results
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for